Platelet Rich Plasma Injection for Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

324 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-01

Study Completion Date

2020-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research questions of this study are;

1. Is platelet rich plasma (PRP) treatment effective in knee osteoarthritis (OA)?
2. What are the indications for PRP treatment?
3. Which patients are the most suitable for the PRP treatment method?
4. How does age, Body Mass Index (BMI), lower extremity mechanical axis angle and OA stages affect the success of the PRP treatment?
5. Is there any advantage of multiple PRP doses?
6. What is the therapeutic effect of placebo?

This study was designed to find answers of these questions.

The hypotheses of this study are; "PRP treatment is more effective than placebo; PRP treatment effectiveness decreases with age and advanced stages of OA; BMI is a factor that negatively affects the treatment effectiveness of the PRP; as the mechanical axis angle of the lower limb increases, it will adversely affect the effectiveness of PRP therapy; multiple dose of PRP affects the effectiveness and duration of PRP as positively compared to single dose of PRP".

The primary purpose of this study; to prove the effectiveness of PRP treatment on knee pain and functions in patients with knee OA by comparing it with the placebo control group. Secondary purposes of this study; to understand the effect of age, BMI, OA grade and lower limb mechanical axis angle on PRP effectiveness. This study, designed as a randomized, double-blind and placebo control group, with a high level of scientific evidence. Thus, it will be scientifically possible to find answers to the investigators research questions and to prove the investigators hypothesis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PRP Effectiveness in Knee Osteoarthritis

NCT04807270

Knee Osteoarthritis

UNKNOWN NA

Knee Osteoarthritis: Platelet Rich Plasma or Hyaluronic Acid

NCT03801564

Knee Osteoarthritis

UNKNOWN NA

Platelet-rich Plasma and Synovial Cytokines in Knee Osteoarthritis

NCT04754685

Knee Osteoarthritis

COMPLETED NA

Comparison of Effectiveness Between PL and PRP on Knee Osteoarthritis: a Prospective,Randomized,Placebo-controlled Trial

NCT03734900

Osteoarthritis (OA) of the Knee

UNKNOWN PHASE4

Efficacy of Mesotherapy Added to Intra-articular Platelet-rich Plasma (PRP) in Patients With Knee Osteoarthritis

NCT05329116

Osteo Arthritis Knee

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The power analysis of this study was calculated based on the sample size studies of previous studies. The difference of d = 3 units between the two means is to have a standard deviation of 6 units. The sample size 200 required to detect with 95% power in the 95% confidence interval to detect.

This study covers 324 patients. All patients were selected according to predefined and established inclusion and exclusion criteria.

Inclusion criteria were: stage 1-2-3 symptomatic OA patients according to Kellgren / Lawrence staging, age between 18 and 80 years, mean Visual Analogue Score (VAS) of \>4 of 10 (worst possible pain) over the course of 7 days during the previous month were included on a voluntary basis. Only one knee injection was made to the patients.

Exclusion criteria were OA secondary to joint inflammatory diseases; patients with generalized OA, metabolic diseases of the bone, coexisting backache, the presence of hematological disease (coagulopathy), bilateral symptomatic lesions and advanced stages (grade 4) of OA; patients who had received intra-articular injections within three months or arthroscopic lavage in the previous one year or who were receiving immunosuppressive; patients with current use of anticoagulant medications or NSAIDs used in the five days before blood donation, major axis deviation (more than 15 degree of varus or more than 5 degree of valgus deviation); and patients with a hemoglobin level less than 11.5 g/dL and platelets level less than 100,000/μL or associated co-morbidities, infection, tumor, crystal arthropathies, anemia, tense joint effusion and pregnancy or possibility of pregnancy.

The voluntary patients included in this study were divided into four different groups with a computer-assisted randomization program. This groups; group A (n:67) were given a single injection of PRP, group B (n:69) were given a single injection of normal saline (physiological control/placebo), group C (n:66) were given three injection (one per month) of PRP, group D (n:65) were given three injection of normal saline (one per month) (physiological control/placebo).

All patients were evaluated by a blinded researcher with VAS, Knee injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), KUJALA, knee range of motion (ROM) and knee circumference measurement at 1st, 3rd, 6th, 12th and 24th months after treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis Cartilage Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP group

Intraarticular 5 ml single PRP injection

Group Type EXPERIMENTAL

PRP

Intervention Type BIOLOGICAL

platelet rich plasma

Saline group

Intraarticular 5 ml single saline injection

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

serum physiologic

Multiple PRP group

Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)

Group Type EXPERIMENTAL

PRP

Intervention Type BIOLOGICAL

platelet rich plasma

Multiple saline group

Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

serum physiologic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRP

platelet rich plasma

Intervention Type BIOLOGICAL

Saline

serum physiologic

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

platelet rich plasma serum physiologic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stage 1-2-3 symptomatic OA patients according to Kellgren / Lawrence staging
* mean VAS pain score of \>4 of 10 (worst possible pain) over the course of 7 days during the previous month

Exclusion Criteria

* OA secondary to joint inflammatory diseases,
* generalized OA,
* metabolic diseases of the bone,
* coexisting backache,
* the presence of hematological disease (coagulopathy),
* bilateral symptomatic lesions and advanced stages (grade 4) of OA,
* patients who had received intra-articular injections within 3 months or arthroscopic lavage in the previous 1 year,
* patients who were receiving immunosuppressive,
* patients with current use of anticoagulant medications,
* NSAIDs used in the 5 days before blood donation,
* major axis deviation (more than 15 degree of varus or more than 5 degree of valgus deviation),
* patients with a hemoglobin level less than 11.5 g/dL,
* platelets level less than 100,000/μL,
* associated comorbidities, infection, tumor, crystal arthropathies, anemia, tense joint effusion and pregnancy or possibility of pregnancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No